Sana has emerged with funding from investors including F-Prime Capital, Arch and Flagship Pioneering to develop genetically modified hypoimmogenic stem cells.
Harvard University’s Office of Technology Development yesterday announced it had executed a licence agreement with its US-based spinout Sana Biotechnology for stem cell medicines resistant to immune system rejection.
Sana Biotechnology launched in January 2019 with an undisclosed sum of funding from F-Prime Capital, a branch of financial services group Fidelity, as well as from VC firms including Arch Venture Partners and Flagship Pioneering.
The company is targeting the development of hypoimmunogenic stem cells to facilitate cell therapies…
